HQL · abrdn Life Sciences Investors
United States · RS rating 32 · As of 2026-10-14
| Price | 17.14 USD |
|---|---|
| 1-day change | -0.7% |
| RS rating (overall / 1M / 3M / 12M) | 32 / 20 / 27 / 64 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 27 / 31 / 20 |
| Industry group (rank) | Finance-Publ Inv Fd-Eqt (87) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +24.4% |
| Market cap (USD) | $529.4M |